Donovan Quill, President and CEO, Optime Care, interview featured on April 5, 2021: Mergermarket
There are over 7,000 rare diseases affecting more than 30 million people in the US, according to the US Food and Drug Administration, most of which do not have adequate treatments. Fewer than 200,000 US patients are affected with orphan disorders, but many diseases are left untreated due to the small populations of people with many genetic disorders.
As a result, many patients and families are left to fight with insurance companies to get often expensive treatments that they need, even though major orphan diseases, such as Duchenne muscular dystrophy, have strong patient advocacy groups.
This article highlights Optime Care’s patient-first business model and how they arrange specialty pharmaceuticals and care regimens for patients with ultra-orphan diseases. Optime currently works with around 5,000 to 8,000 patients a year and multi-disciplinary care teams that have been highly effective in obtaining insurance funding.
